The EU Commission conditionally clears a merger leading to the creation of the largest European producer of generic medicines (Novartis / Hexal / Eon Labs)

"Mergers — Main developments between 1 May and 31 August 2005"* The Commission authorised the acquisition of Hexal, a German producer of generic medicines, and its US sister company Eon Labs by Novartis, in a deal which creates the largest European producer of generic medicines. The clearance was subject to a number of conditions intended to safeguard competition and hence the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • JG Associates (Brussels)
  • DG COMP (Brussels)

Quotation

John Gatti, Mary Loughran, The EU Commission conditionally clears a merger leading to the creation of the largest European producer of generic medicines (Novartis / Hexal / Eon Labs), 27 May 2005, e-Competitions May 2005, Art. N° 38284

Visites 363

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues